BeiGene Announces Pricing of $200 Million Public Offering

WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of its follow-on public offering of 6,250,000 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $32.00 per ADS.  BeiGene is offering 5,781,250 ADSs, and certain selling shareholders are offering 468,750 ADSs. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 937,500 ADSs from BeiGene. The offering is expected to close on November 23, 2016, subject to customary closing conditions.

BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities. BeiGene will not receive any of the proceeds from any sale of ADSs by the selling shareholders.

Morgan Stanley, Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers. Baird and William Blair & Company L.L.C. are acting as co-managers.

The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. The registration statement can be accessed through the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800
[email protected]
[email protected]

You May Also Be Interested In

• Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh
• Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
• Asset Entities Inc (ASST) Files S-3